• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Gene Therapy of Critical Limb Ischemia Enters Clinical Use.肢体严重缺血的基因治疗进入临床应用阶段。
Mol Ther. 2019 Dec 4;27(12):2053. doi: 10.1016/j.ymthe.2019.11.001. Epub 2019 Nov 13.
2
Safety of vascular endothelial and hepatocyte growth factor gene therapy in patients with critical limb ischemia.血管内皮和肝细胞生长因子基因治疗在严重肢体缺血患者中的安全性。
Curr Neurovasc Res. 2011 Aug 1;8(3):183-9. doi: 10.2174/156720211796558050.
3
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia.随机、双盲、安慰剂对照的肝细胞生长因子治疗严重肢体缺血的 II 期研究。
Mol Ther. 2019 Dec 4;27(12):2158-2165. doi: 10.1016/j.ymthe.2019.10.017. Epub 2019 Oct 31.
4
Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.一项双盲、安慰剂对照研究的结果，该研究旨在评估肌肉注射肝细胞生长因子质粒改善严重肢体缺血患者肢体灌注的安全性。
Circulation. 2008 Jul 1;118(1):58-65. doi: 10.1161/CIRCULATIONAHA.107.727347. Epub 2008 Jun 16.
5
Clinical Safety and Preliminary Efficacy of Plasmid pUDK-HGF Expressing Human Hepatocyte Growth Factor (HGF) in Patients with Critical Limb Ischemia.质粒 pUDK-HGF 表达人肝细胞生长因子（HGF）治疗严重肢体缺血患者的临床安全性和初步疗效。
Eur J Vasc Endovasc Surg. 2015 Oct;50(4):494-501. doi: 10.1016/j.ejvs.2015.05.007. Epub 2015 Jun 27.
6
Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia.随机、双盲、安慰剂对照临床试验研究肝细胞生长因子质粒治疗严重肢体缺血。
Gene Ther. 2010 Sep;17(9):1152-61. doi: 10.1038/gt.2010.51. Epub 2010 Apr 15.
7
Double VEGF/HGF Gene Therapy in Critical Limb Ischemia Complicated by Diabetes Mellitus.双重 VEGF/HGF 基因治疗合并糖尿病的肢体严重缺血。
J Cardiovasc Transl Res. 2021 Jun;14(3):409-415. doi: 10.1007/s12265-020-10066-9. Epub 2020 Sep 1.
8
Combined Analysis of Clinical Data on HGF Gene Therapy to Treat Critical Limb Ischemia in Japan.日本 HGF 基因治疗治疗严重肢体缺血的临床数据分析综合
Curr Gene Ther. 2020;20(1):25-35. doi: 10.2174/1566523220666200516171447.
9
Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial.患者特异性肌肉内注射 HGF 质粒基因治疗对缺血性下肢溃疡患者肢体灌注和创面愈合的安全性和疗效：HGF-0205 试验结果。
J Vasc Surg. 2010 Dec;52(6):1525-30. doi: 10.1016/j.jvs.2010.07.044.
10
Progress of Gene Therapy in Cardiovascular Disease.心血管疾病的基因治疗进展。
Hypertension. 2020 Oct;76(4):1038-1044. doi: 10.1161/HYPERTENSIONAHA.120.14478. Epub 2020 Aug 10.

引用本文的文献

1
Breaking barriers in the sensitive and accurate mass determination of large DNA plasmids by mass photometry.通过质量光度法在大型DNA质粒灵敏且准确的质量测定方面突破障碍。
Mol Ther Nucleic Acids. 2025 Jul 17;36(3):102632. doi: 10.1016/j.omtn.2025.102632. eCollection 2025 Sep 9.
2
Extended Toxicity, Genotoxicity, and Mutagenicity of Combination of pBudK-coVEGF-coANG and pBudK-coGDNF Plasmids in Preclinical Trials.pBudK - coVEGF - coANG与pBudK - coGDNF质粒组合在临床前试验中的长期毒性、遗传毒性和致突变性
Biomedicines. 2025 May 18;13(5):1223. doi: 10.3390/biomedicines13051223.
3
Exploring precision treatments in immune-mediated inflammatory diseases: Harnessing the infinite potential of nucleic acid delivery.探索免疫介导的炎症性疾病的精准治疗：发挥核酸递送的无限潜力。
Exploration (Beijing). 2024 May 24;5(1):20230165. doi: 10.1002/EXP.20230165. eCollection 2025 Feb.
4
Review on the bioanalysis of non-virus-based gene therapeutics.基于非病毒的基因治疗药物的生物分析综述。
Bioanalysis. 2024 Dec-Dec;16(23-24):1279-1294. doi: 10.1080/17576180.2024.2437418. Epub 2024 Dec 14.
5
Translational Relevance of Advanced Age and Atherosclerosis in Preclinical Trials of Biotherapies for Peripheral Artery Disease.外周动脉疾病生物疗法临床前试验中高龄与动脉粥样硬化的转化相关性
Genes (Basel). 2024 Jan 22;15(1):135. doi: 10.3390/genes15010135.
6
Sequence-independent, site-specific incorporation of chemical modifications to generate light-activated plasmids.化学修饰的序列非依赖性、位点特异性掺入以生成光激活质粒。
Chem Sci. 2023 Oct 13;14(44):12693-12706. doi: 10.1039/d3sc02761a. eCollection 2023 Nov 15.
7
Stimuli-Responsive Non-viral Nanoparticles for Gene Delivery.用于基因递送的刺激响应性非病毒纳米颗粒
Handb Exp Pharmacol. 2024;284:27-43. doi: 10.1007/164_2023_694.
8
IGF-1 Therapy Improves Muscle Size and Function in Experimental Peripheral Arterial Disease.胰岛素样生长因子-1疗法可改善实验性外周动脉疾病中的肌肉大小和功能。
JACC Basic Transl Sci. 2023 Mar 8;8(6):702-719. doi: 10.1016/j.jacbts.2022.12.006. eCollection 2023 Jun.
9
Two-Stage Gene Therapy (VEGF, HGF and ANG1 Plasmids) as Adjunctive Therapy in the Treatment of Critical Lower Limb Ischemia in Diabetic Foot Syndrome.两阶段基因治疗（VEGF、HGF 和 ANG1 质粒）作为糖尿病足综合征下肢严重缺血治疗的辅助治疗。
Int J Environ Res Public Health. 2022 Oct 6;19(19):12818. doi: 10.3390/ijerph191912818.
10
In silico performance analysis of web tools for CRISPRa sgRNA design in human genes.用于人类基因CRISPRa sgRNA设计的网络工具的计算机性能分析
Comput Struct Biotechnol J. 2022 Jul 13;20:3779-3782. doi: 10.1016/j.csbj.2022.07.023. eCollection 2022.

本文引用的文献

1
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia.随机、双盲、安慰剂对照的肝细胞生长因子治疗严重肢体缺血的 II 期研究。
Mol Ther. 2019 Dec 4;27(12):2158-2165. doi: 10.1016/j.ymthe.2019.10.017. Epub 2019 Oct 31.
2
Therapeutic Angiogenesis With Intramuscular NV1FGF Improves Amputation-free Survival in Patients With Critical Limb Ischemia.肌肉注射 NV1FGF 进行治疗性血管生成可改善严重肢体缺血患者的无截肢生存率。
Mol Ther. 2008 May;16(5):972-978. doi: 10.1038/mt.2008.33. Epub 2016 Dec 8.
3
Beperminogene perplasmid for the treatment of critical limb ischemia.用于治疗严重肢体缺血的质粒介导贝泊基因
Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56. doi: 10.1586/14779072.2014.955850. Epub 2014 Sep 5.
4
Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.一项双盲、安慰剂对照研究的结果，该研究旨在评估肌肉注射肝细胞生长因子质粒改善严重肢体缺血患者肢体灌注的安全性。
Circulation. 2008 Jul 1;118(1):58-65. doi: 10.1161/CIRCULATIONAHA.107.727347. Epub 2008 Jun 16.
5
Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease.使用肝细胞生长因子治疗外周动脉疾病的临床基因治疗的安全性评估。
Hypertension. 2004 Aug;44(2):203-9. doi: 10.1161/01.HYP.0000136394.08900.ed. Epub 2004 Jul 6.
6
Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study.血管内皮生长因子基因转染人下肢动脉后数字减影血管造影检测到血管增多：一项随机、安慰剂对照、双盲的II期研究。
Mol Ther. 2002 Jul;6(1):127-33. doi: 10.1006/mthe.2002.0638.

Gene Therapy of Critical Limb Ischemia Enters Clinical Use.

作者信息

Ylä-Herttuala Seppo

机构信息

A.I. Virtanen Institute, University of Eastern Finland, 70211 Kuopio, Finland.

出版信息

Mol Ther. 2019 Dec 4;27(12):2053. doi: 10.1016/j.ymthe.2019.11.001. Epub 2019 Nov 13.

DOI:10.1016/j.ymthe.2019.11.001
PMID:31732297
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6904627/
Abstract
摘要